FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

The FDA recently solidified its leadership by appointing permanent directors for CBER and CDER, aiming to restore institutional stability following recent regulatory controversies. Concurrently, the agency is prioritizing the regulation of psychedelic therapies and the reshoring of early-stage clinical trials through the Operation TrialBlazer initiative and upcoming PDUFA 8 negotiations. At the World Conference on Lung Cancer, companies reported significant survival improvements, notably with therapies from BeyondTech and GSK. Meanwhile, the pharmaceutical sector faces volatility following a series of late-stage trial failures at Novartis, which triggered broader market declines. In corporate shifts, Novo Nordisk has rebranded to "Novo," signaling a strategic pivot toward a forward-looking culture ahead of its upcoming capital markets day. These developments highlight a period of intense regulatory scrutiny, clinical innovation, and corporate restructuring across the biopharmaceutical landscape.